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OVERVIEW
Precision Medicine: From Science
To Value
ABSTRACT Precision medicine is making an impact on patients, health
care delivery systems, and research participants in ways that were only
imagined fifteen years ago when the human genome was first sequenced.
Discovery of disease-causing and drug-response genetic variants has
accelerated, while adoption into clinical medicine has lagged. We define
precision medicine and the stakeholder community required to enable its
integration into research and health care. We explore the intersection of
data science, analytics, and precision medicine in the formation of health
systems that carry out research in the context of clinical care and that
optimize the tools and information used to deliver improved patient
outcomes. We provide examples of real-world impact and conclude with a
policy and economic agenda necessary for the adoption of this new
paradigm of health care both in the United States and globally.
I
n 2011 the National Research Council’s
Toward Precision Medicine adopted the
following definition of precision medi-
cine: “The tailoring ofmedical treatment
to the individual characteristics of each
patient…to classify individuals into subpopula-
tions that differ in their susceptibility to a par-
ticular disease or their response to a specific
treatment. Preventative or therapeutic interven-
tions can then be concentrated on thosewhowill
benefit, sparing expense and side effects for
those who will not.”1 As this definition suggests,
the power of precisionmedicine lies in its ability
to guide health care decisions toward the most
effective treatment for a given patient and, thus,
improve care quality while reducing the need for
unnecessary diagnostic testing and therapies.
Precision Medicine Is Data-Science
Driven
The rise of electronic medical records (EMRs)
and robust information technology (IT) systems
supporting both research and health care deliv-
ery has placed patients and research participants
who agree to provide biospecimens and share
their clinical and research data at the epicenter
of precision medicine research.2 The data de-
rived from EMRs and biospecimens generate
new findings that are linked to digital pheno-
types derived frommobile and wearable devices,
family history, and environmental exposures.
These can all be captured as part of clinical care.
Clinicians can use this growing knowledge base,
which is oftenmaintained and curated at clinical
laboratories.3–6 The assembly of genomic, envi-
ronmental, digital health, and patient-reported
data from a variety of sources serves as the foun-
dation for a powerful precision medicine plat-
form that, when coupled to other national and
global data and clinical networks, will lead to the
dissemination of knowledge that will enable oth-
er health care delivery systems to benefit.7 When
such systems are fully developed, clinical prac-
tice and research will be able to inform each
other, with the goal of improving the efficiency
and effectiveness of disease prevention, diagno-
sis, and treatment.8
The precision medicine community must
shape thedata systemsand thedata science strat-
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egies forhow thedata areused. Providers require
information at the point of decision so they can
use it in the context of their clinical workflow,
and patients must clearly state their preferences
about the use and sharing of their genomic and
other information with researchers and others
beyond the delivery system in which they receive
care. Researchers will identify and adopt best
practices for research using EMR-linked geno-
mic information. Health systems will offer pro-
viders tools and systems that enable them to
make more informed decisions. The health IT
community must design secure and interopera-
ble genomics-enabled systems for actionable
use in both health care and community settings.
Policy makers will address the return of results,
privacy, confidentiality, and education while de-
veloping regulations and economic incentives
that can align the interests of all stakeholders.
Data Sharing Is A High-Payoff
Strategy
Several ongoing efforts in the US public and
private sectors are aimed at establishing data
repositories for large-scale EMR-linked genomic
information.9,10 Making data standardized, com-
parable, and consistent facilitates the data’s re-
use for discovery in multiple contexts beyond
their original use. For example, the combination
of data in the EMR and gene sequencing infor-
mation has been a powerful tool for identifying
genetic variants associated with disease and for
understanding individual responses to thera-
pies.11 The economics of data sharingmight seem
obvious: If a health system shares 100 genomes
and patient records with ten other systems that
agree to do the same, each gains 1,000 genomes
and records for the cost of generating 100.8 The
power of genomics-enabled research and health
care is proportional to the amount of data that
can be accessed and analyzed.
Health care systems supporting cycles that
encompass both the analysis of data to produce
results and the use of those results to develop
changes in clinical practice are systems that will
allow optimal learning.12 Combining informa-
tion about all people in such systems, genomic
data could inform strategies to improve popula-
tion health and contribute to care management.
Including physicians in these systems of clinical
decision support, guidelines for clinical action,
and more information on the clinical utility of
genetic testing would help them make effective
use of genomic information and integrate it into
their practice as they have donewith othermedi-
cal test information.
Precision Medicine—Where Are We
Today?
A number of applications of precision medicine
currently contribute to health care at many
points across the lifespan. Genetic screening
maybeused before conception to predict the risk
of passing on genetic disorders to offspring.13,14
At eight to twelve weeks’ gestation, noninvasive
prenatal testing may be used to screen for
trisomy 13, 18, and 21 in the fetus (all causing
developmental abnormalities), and even whole-
genome sequencing of the fetus has been per-
formed.15 At birth, sequencing has been used to
rapidly diagnose many critical conditions for
which there could be actionable results, leading
to reduced morbidity and mortality.16 Later in
life, these approaches can be used to diagnose
a variety of diseases, most notably the detection
of circulating tumor cell DNA (a process also
known as a liquid biopsy) to diagnose cancer.17,18
Many genomic markers of efficacy, adverse
events, and dosing of therapeutics have been
discovered and recommended for clinical use,
but their uptake into clinical practice has been
variable, even when their actionability has been
supported by evidence. In some cases, people
who are carriers of the HLA-B*5701 or HLA-
B*1502 genotype, variants of a gene complex
that plays a critical role in the immune system,
should avoid the HIV drug abacavir and the
antiseizure drug carbamazepine, respectively,
to avoid serious adverse events. In other cases,
such as people with variants in the TPMT gene
for mercaptopurine, used to treat some cancers
and autoimmune diseases) or in CYP2C9/
VKORC1 for warfarin (used to prevent or treat
blood clots), adjusting the dose of drug based on
genotype can help to avoid toxicity and improve
efficacy. However, actionability is not enough to
ensure clinical uptake of pharmacogenetic test-
ing. This is demonstrated by the fact that there is
no clear consensus among physicians on the use
of the antiplatelet drug clopidogrel (also used to
treat blood clots), despite its having a Food and
DrugAdministration (FDA) “blackboxwarning”
of varying efficacy among people carrying differ-
ent CYP2C19 genetic variants. For established
drugs, the use of genetic markers that predict
therapeutic efficacy may face a high hurdle,
unless there is strong evidence of a test’s clinical
utility to drive provider acceptance.
New Research Initiatives In
Translational Precision Medicine
To identify and overcome the barriers in trans-
lating genome-based discoveries into clinical
practice, the National Human Genome Research
Institute has funded several initiatives (de-
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scribed below) that focus on implementation,
evidence generation, and health policy in geno-
mics and precision medicine.
Electronic Medical Records And Genomics
Established in 2007, the Electronic Medical
Records and Genomics (eMERGE) Network19
was the first major National Human Genome
Research Institute consortium developed to ex-
plore the utility of DNA repositories coupled to
EMRs for advancing discovery as well as to ad-
dress the policy issues related to this strategy for
precision medicine research. eMERGE created
an electronic phenotyping library, the Pheno-
type KnowledgeBase, and initiated integration
of actionable variants into EMRs for use in clini-
cal care. More recently, a series of pilot demon-
stration projects were initiated to investigate the
utility of pharmacogenetics variants to guide
treatment using EMR-integrated clinical deci-
sion support tools.
Clinical Sequencing Evidence-Generating
Research The Clinical Sequencing Evidence-
Generating Research (CSER) consortium20 was
formed in 2011 to develop methods for integrat-
ing genome sequencing into clinical medicine,
improving the discovery and interpretation of
genomic variants, and investigating the impact
of genome sequencing on health care outcomes.
The consortium has defined, generated, and
analyzed evidence regarding the clinical utility
of genome sequencing; investigated the inter-
actions among patients, family members, health
care practitioners, and clinical laboratories that
influence implementation of clinical genome
sequencing; and identified and addressed real-
world barriers to integrating genomic, clinical,
and health care utilization data within a health
care system to build a shared evidence base for
clinical decision making.
CSER has used genome sequencing in diverse
care settings and populations for prenatal test-
ing and for the evaluation of newborns, healthy
people, andpatientswith cardiovasculardisease;
it has also made substantial progress in building
the evidence base for clinical sequencing.21 After
the initial studies tested the feasibility of imple-
menting genome sequencing into clinical care,
studies arenowexamining the utility of sequenc-
ing information. There is also a focus on recruit-
ing members of diverse racial and ethnic groups
and historically underrepresented groups into
genomics research,22 as well as an emphasis on
studying diverse clinical health care settings.
Implementing Genomics In Practice Imple-
menting Genomics in Practice (IGNITE)23 was
formed in2013 to address the challenges towide-
spread clinical implementation of genomicmed-
icine, a prerequisite for developing evidence of
its real-world utility. IGNITE has investigated
and disseminated genomic medicine practice
models that seamlessly integrate genomic data
into the EMR and deploy tools for point-of-care
decision making. In addition to creating novel
educational approaches, the projects include the
use of validated genetic markers for disease risk
prediction and prevention (for example, the use
of the ApoLI genetic variant as a marker for
kidney disease in African Americans with hyper-
tension to promote control of hypertension), the
implementation of electronic family history
tools with clinical decision support,24 and the
use of pharmacogenetic data to guide the use
of medications (for example, CYP2C19 variants
for clopidogrel and CYP2D6 variants for pain
medication management).
Initial lessons learned from IGNITE include
the following: Implementation science requires
both a transdisciplinary team with the right ex-
pertise and an implementation framework, and
implementation frameworks guide intervention
deployment, assessment, and analyses. IGNITE
adopted and adapted the Consolidated Frame-
work for Implementation Research.25 Pre-imple-
mentation research is often overlooked as a
critical element to ensure that researchers un-
derstand and take into account the priorities,
concerns, and educational needs of the setting
and clinical personnel before implementation
begins. Genomic medicine research is IT inten-
sive. Broad implementation of genomic medi-
cine requires that IT solutions work with an
EMR to either incorporate genomic information
into it or extract phenotypic data from it. Thus,
IT leadership at the implementing institution
needs to prioritize its incorporation.
Precision Medicine—A National
Research Agenda
In 2015 President Barack Obama announced a
government-funded precision medicine initia-
tive thatwill enroll over amillionpeople. Inwhat
is now called the All of Us Research Program,9
participants are expected to share the data gen-
erated or captured over more than ten years by
sequencing, EMRs, personally reported infor-
mation, and digital health technologies. These
data will be the subject of analyses intended to
drive both a novel scientific agenda to increase
understanding of the underlyingmechanisms of
disease and an agenda for data- and precision-
driven health care for individuals and popula-
tions. Both agendas should contribute to a novel
paradigm of health care expected to affect health
and decisions across the lifespan.
Influencing the launch of All of Us was a dra-
matic decline in the cost and increase in through-
put of DNA sequencing,26 the near-ubiquitous
Precision Medicine
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adoptionofEMRsacross theUnitedStates,27 and
the growth of digital health technologies as a
source of continuous and rich personal data.28
Other genome-based technology platforms (for
example, RNA assays) are also increasingly be-
ing used as diagnostic tests to classify disease
states (for example, a blood RNA assay is used
to diagnose rejection following a heart trans-
plant without the need for an endomyocardial
biopsy)29 andasprognostic tests topredict future
clinical outcomes (for example, an tumor RNA
assay is used to predict prognosis and guide
treatment strategies in breast cancer).30 Togeth-
er, these approaches form the basis for a new
molecular taxonomy of disease; provide more
precise ways to screen for and detect disease
at its earliest molecular manifestations, often
preclinically; and allow the selection of certain
drugs tobeguidedby apatient’s geneticmakeup.
In the future, it is likely that periodic molecular
and digital profiling will shift the focus of health
care strategies from acute intervention and dis-
ease management to assessing health and the
proactive management of disease risks and pre-
vention.
Global Efforts To Implement
Precision Medicine
Efforts and initiatives are under way worldwide
to create national implementation strategies for
genomicmedicine (exhibit 1).31 Key barriers that
exist to implementing and integrating precision
medicine technologies into health care practice
include the absence of supporting IT infrastruc-
ture, lack of data standards and system interop-
erability, insufficient decision support technol-
ogy, and insufficient funding for translational
health research. Policies to support progress in
these areas will be critical to the adoption and
integration of precision medicine technologies
into health care worldwide and the collaborative
frameworks to support it as a global agenda.
A Policy Agenda For Precision
Medicine
To fully realize the integration of precision med-
icine into health care, stakeholders must now
implement an agenda32–34 that supports evidence
generation, data sharing and its integration into
health care, regulation, reimbursement, eco-
nomic value, and participant engagement.
Evidence Generation If it is to be widely
adopted, precision medicine will require high-
quality evidence that it improves patient out-
comes. There are currently more than 75,000
unique genetic testing products on the market,
and an average of ten new products are added
each day.35 The market for clinical sequencing—
which encompasses the use of sequencing tests
for diagnosis, risk prediction, therapy selection
and monitoring, and screening—is growing at a
compound annual rate of 28 percent.35 Thus,
while the initiatives described above will contin-
ue to provide new evidence, the rapid evolution
and availability of novel technologies and the
growth of multigene panels require innovative
strategies to develop evidence.
The challenge is how to obtain the needed
evidencewhen the field is growing and changing
so rapidly that the “gold standard” of large ran-
domized clinical trials may be unfeasible. Alter-
natives have been proposed that offer creative
approaches to generating evidence, such as
new models of risk sharing and evidence devel-
opment among technology developers, health
care systems, and payers.36 As an example, the
Centers for Medicare and Medicaid Services
(CMS) had published twenty two “coverage
with evidence development” policies by Decem-
ber 2016.37 However, there can be no one-size-
fits-all approach for evidence generation, since
the evidentiary threshold will vary with the risk
of the test and the financial impact on the stake-
holders.
Data Sharing And Integration Precision
medicine will require access to large-scale, de-
tailed, and highly integrated patient data. Many
initiatives are focused on increasing the interop-
erability of systems that generate and manage
patient data and enhancing those systems for
use at the point of care.38 Although great strides
have made in recent years toward achieving a
paperless health care system based on EMRs,
much more needs to be done to integrate data
across systems and to mine data that already
exist but remain in silos. The National Institutes
ofHealth (NIH)needs to facilitate cross-site data
integration for research, while health systems
must do the same for the optimization of patient
care.
Many different sectors and activities have to
coalesce to promote the implementation and
adoption of precision medicine, including the
appropriate education, data systems, coverage
and reimbursement policies, health systemproc-
esses, and health policies. These issues are rele-
vantnotonly to theUSbut also toothercountries
and regions that are implementing precision
medicine or are likely to do so in the near future
(see exhibit 1). Initiatives such as the All of Us
Research Program in the US and the Genomics
England project have been widely publicized,
but less attention has been paid to other global
initiatives and opportunities. For example,
France recently committed $700 million to fund
sequencing centers, and China has committed
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Exhibit 1
Selected programs to implement precision medicine in 13 countries
Country, name of project, and website Goals of program
Australia
Australian Genomics Health Alliance, https://www
.australiangenomics.org.au
Develop national framework for translating -omics discoveries into clinical
research and practice, incorporating advice on return of results from genomics
research and clinical testing.
Belgium
Belgian Medical Genomics Initiative, https://biblio.ugent.be/project/
120C03412
Predict clinical outcomes from genomic information and fulfill a pilot role toward
concerted integration of genomic information in clinical care in Belgium.
Canada
GenomeCanada, https://www.genomecanada.ca/ Carry out large-scale research projects focused on the application of genomics in
the area of precision health. Precision health can be seen as an evidence-
based approach to decision making with regard to health care and public
health.
Estonia
Estonian Program for Personal Medicine, https://www
.geenivaramu.ee/en
Sequence 5,000 people, develop an Estonian genotyping array, pilot of 50,000
Estonian Biobank members, offer to all ages 35–65 (about 500,000 people)
and link to EMR.
France
Plan France Médecine Génomique 2025, https://aviesan.fr/fr/
aviesan/accueil/toute-l-actualite/plan-france-medecine-
genomique-2025
Use the integration of patient care, training, and research to allow access to
genomic medicine to all concerned (patients and their families as indicated).
By 2020, 235,000 genomes will be sequenced each year.
Israel
Bench-to-Bedside Project, https://www.weizmann.ac.il/
WeizmannCompass/sections/features/the-bench-to-bedside-
project
Sequence 100,000 Israeli genomes from selected patients (this is a project of
the Weizmann Institute of Science and Clalit Health Systems).
Japan
Implementation of Genomic Medicine Project, http://
www.src.riken.jp/english/project/person/
Use genomics for optimized diagnosis, treatment, and prevention.
Korea
Genome Technology to Business Translation Program, http://
www.cdc.go.kr/NIH/eng/main.jsp
Use genomics to develop early diagnosis and treatment approaches for
personalized and preventive medicine.
Luxembourg
Centre for Systems Biomedicine, https://wwwfr.uni.lu/recherche/
priorites_de_recherche/luxembourg_centre_for_systems_
biomedicine_lcsb
Focus on early diagnosis and stratification of Parkinson disease.
Singapore
Personalized OMIC Lattice for Advanced Research and Improving
Stratification, https://www.a-star.edu.sg/polaris/
Pilot TGFBI gene testing for disease diagnosis and family risk assessment in
stromal corneal dystrophies, then implement a 90-gene panel for
gastrointestinal cancers.
Thailand
Pharmacogenomics Network, http://www.thailandpg.org/ Implement pharmacogenomics card to identify risk of using top ten drugs
associated with SJS/TEN, integrated with nationwide pharmacovigilance
program.
United Kingdom
Genomics England, http://www.genomicsengland.co.uk/ Sequence 100,000 whole genomes and link to National Health Service records to
treat individual patients and better understand cancer and rare and infectious
diseases.
United States
All of Us Research Program, https://allofus.nih.gov/ Recruit one million participants representative of the population and share data
from their EMRs, digital health technologies, and genomics to enhance
scientific discovery and clinical care.
SOURCE Adapted from Manolio TA, et al. Global implementation of genomic medicine (see note 31 in text). NOTES EMR is electronic medical record. SJS/TEN is Stevens-
Johnson syndrome/toxic epidermal necrosis.
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up to $10 billion to fund its precision medicine
initiative.39 However, there are few published
studies on implementation outside of well-
known countries, and thus more research is
needed to examine the implementation of preci-
sion medicine and to disseminate lessons
learned and best practices across countries to
enhance their impact on diverse patients and
populations.
Regulation A key topic for future discourse
will be the evolving regulatory landscape for pre-
cision medicine tests. There continues to be un-
certainty about how the FDAwill regulatemolec-
ular and genomic tests. There is also uncertainty
about the extent to which the FDA will increase
its oversight over laboratory-developed tests,
which do not require FDA approval. Most preci-
sion medicine tests are currently laboratory
developed. A related challenge for the FDA will
be to develop its approach to regulating diagnos-
tics that incorporate sequencing technologies,
as these tests will require flexible and evolving
regulatory approaches.34 The FDA has recently
moved forward on tackling this challenge
through the use of parallel review with CMS
for sequencing tests.40 The FDA and CMS will
need to develop and refine approaches to regu-
lation and coverage that give precisionmedicine
tests the most effective pathway to the clinic.
Reimbursement And Economics As is the
case for all new health care interventions, imple-
mentation of precision medicine will be stymied
if such interventions do not provide demonstrat-
ed valueor if payers andconsumers areunwilling
to pay for them. There remain many challenges
to determining whether and when precision
medicine provides sufficient value relative to
its costs, and whether payers should reimburse
for testing.
The second author and her colleagues recently
analyzed private payers’ coverage policies for
genetic tests that measure multiple genes (such
as panel or whole-exome sequencing tests) and
found that there is limited and variable coverage
of such tests,41 although a more recent unpub-
lished analysis indicates that some tests are in-
creasingly being covered.42 A study on preemp-
tive pharmacogenetic testing found that one
reason why payers hesitate to cover such tests
is that they do not fit most payers’ “mental mod-
els” for coverage decisions.43 The authors con-
cluded that prospective outcome studies, more
precisely defined target populations, and predic-
tive economic models are important considera-
tions for future research.
Demonstrating the economic value and afford-
ability of precisionmedicine tobothpatients and
organizations is a critical issue that remains in
needof further research. For example, anunpub-
lished assessment of the current knowledge base
about the economics of precision medicine42 in-
dicates that the number of economic evaluations
of precision medicine is increasing, although
evidence of its economic value is still relatively
limited, and there are many gaps in the topics
covered. Studies have found that precision
medicine interventions are generally similar in
cost-effectiveness to other types of health care
interventions: A majority of interventions have
been found to be cost-effective relative to stan-
dard practice, but only aminority of studies have
found precision medicine to be cost saving.44
To better assess the economic value of precision
medicine, a number of methodological chal-
lenges should be addressed, such as identifying
relevant studies, dealing with variability across
studies, and broadening the focus of studies to
other conditions. Thus, to move ahead on a poli-
cy agenda for reimbursement and economic val-
ue, payers and industry need to work together to
develop the necessary evidence base.
Participant Engagement Importantly, pa-
tients and consumers must participate in preci-
sion medicine for it to achieve its potential. The
adoption of precision medicine raises many
questions related to patient engagement, and
the critical elementof trust, including the follow-
ing: What constitutes truly informed consent?
Who owns genetic information and shouldmake
decisions about what results are returned to
them, and how the results are used? How can
privacy be ensured?What outcomesmatter most
to patients?
A focus of future work should be increasing
the emphasis on the ability of precisionmedicine
to affect not only individuals but also popula-
tions—what has been termed “precision public
health.”45,46 The initial drive toward precision
public health is under way, but muchmore work
lies ahead to develop a robust evidentiary foun-
dation for its use.45 Another area of emphasis
should be increased understanding of how
The democratization
of data underpins the
scientific advances
that enable not only
precision medicine but
medicine itself.
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precision medicine could widen or narrow the
historical disparities in access to care. Do histor-
ically unserved populations have access to preci-
sion medicine, and what policies could ensure
appropriate access? These questions will need to
be addressed within the larger and shifting con-
text of health reform and proposed revisions to
Medicaid programs.
An Action Plan For Precision
Medicine
The full realization of precision medicine’s dis-
ruptive potential will require a multipronged
scientific, clinical, and policy agenda. The de-
mocratization of data underpins the scientific
advances that enable not only precision medi-
cine but medicine itself. Proper incentives for
the sharing of data will be required. The preci-
sion medicine community—participants, pa-
tients, providers, payers, and regulators—will
require evidence of value in terms of quality of
life, quality of medical care, and cost efficiency
and cost-effectiveness. If precision medicine is
successful, more care will occur before disease is
apparent, in a shift from disease treatment to
diseasepreventionandearlydetection. Precision
medicine is not uniquely American—it is on the
global agenda31—and for it to reach its rightful
place in health and society will require global
leadership and perseverance.
All stakeholders have a role in developing ap-
propriate policies: Researchers need to examine
lessons learned on implementation both in the
US and globally and to assess the impact on both
patients and populations; payers and industry
need to work together to develop the necessary
evidence base; the NIH needs to facilitate cross-
site data integration for research, while health
systemsmust do the same for theoptimizationof
patient care; and the FDA and CMS need to de-
velop and refine approaches to regulation and
coverage that give precision medicine tests the
most effective pathway to the clinic. ▪
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